Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,355.76 +8.77 (+0.16%) Dow
38,826.83 +27.84 (+0.07%) Nasdaq
17,166.99 +33.87 (+0.20%) Bitcoin USD
69,825.38 +118.47 (+0.17%) CMC Crypto 200
1,449.36 +2.69 (+0.19%)
AstraZeneca PLC (AZNCF)
| Previous close | 160.10 |
| Open | 160.00 |
| Bid | 154.05 x 40000 |
| Ask | 165.05 x 40000 |
| Day's range | 159.90 - 160.10 |
| 52-week range | 118.16 - 160.10 |
| Volume | |
| Avg. volume | 3,269 |
| Market cap | 249.889B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 39.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.86 (1.79%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Business Wire
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
WILMINGTON, Del., June 10, 2024--AstraZeneca’s supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If approved, TAGRISSO will be indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations.
- PR Newswire
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.
- PR Newswire
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation shared data indicati
